Manuela Battaglia

List of Publications by Year in Descending Order

102 papers	8,499 citations	42 h-index	92 g-index
107 ext. papers	9,545 ext. citations	7.8 avg, IF	5.87 L-index

#	Paper	IF	Citations
102	Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice.. *JCI Insight*, **2022**, 7,	9.9	2
101	Exocrine pancreas function is impaired in adult relatives of patients with type 1 diabetes. *Acta Diabetologica*, **2021**, 1	3.9	0
100	Reduced Follicular Regulatory T Cells in Spleen and Pancreatic Lymph Nodes of Patients With Type 1 Diabetes. *Diabetes*, **2021**, 70, 2892-2902	0.9	3
99	Identifying the 'Achilles heel' of type 1 diabetes. *Clinical and Experimental Immunology*, **2021**, 204, 167-178	6.2	0
98	Impaired exocrine pancreatic function in different stages of type 1 diabetes. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	3
97	Altered Frequency and Phenotype of HLA-G-Expressing DC-10 in Type 1 Diabetes Patients at Onset and in Subjects at Risk to Develop the Disease. *Frontiers in Immunology*, **2021**, 12, 750162	8.4	1
96	CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes. *JCI Insight*, **2021**, 6,	9.9	5
95	Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. *Clinical and Experimental Immunology*, **2020**, 201, 222-230	6.2	5
94	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. *Diabetes Care*, **2020**, 43, 5-12	14.6	111
93	Reduced PD-1 expression on circulating follicular and conventional FOXP3 Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children. *Clinical Immunology*, **2020**, 211, 108319	9	11
92	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. *Diabetes*, **2019**, 68, 1267-1276	0.9	45
91	Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function. *Journal of Translational Medicine*, **2019**, 17, 250	8.5	2
90	Neutrophils and type 1 diabetes: current knowledge and suggested future directions. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2019**, 26, 201-206	4	14
89	Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. *European Journal of Immunology*, **2018**, 48, 1389-1399	6.1	11
88	Islet-reactive CD8 T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. *Science Immunology*, **2018**, 3,	28	98
87	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves -Cell Function and Improves HbA in New-Onset Type 1 Diabetes. *Diabetes Care*, **2018**, 41, 1917-1925	14.6	56
86	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. *Diabetes Care*, **2018**, 41, 1887-1894	14.6	59

85	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*, **2018**, 3,	9.9	50
84	Murine Pancreatic Islets Transplantation under the Kidney Capsule. *Bio-protocol*, **2018**, 8, e2743	0.9	1
83	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. *Immunity*, **2018**, 49, 1004-1019	32.3	123
82	Protein tyrosine phosphatase PTPN22 has dual roles in promoting pathogen versus homeostatic-driven CD8 T-cell responses. *Immunology and Cell Biology*, **2017**, 95, 121-128	5	8
81	IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo. *Journal of Immunology*, **2017**, 198, 1130-1141	5.3	62
80	Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. *Nature Immunology*, **2017**, 18, 1321-1331	19.1	127
79	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. *Frontiers in Immunology*, **2017**, 8, 1844	8.4	34
78	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Scientific Reports*, **2017**, 7, 6897	4.9	34
77	Understanding and preventing type 1 diabetes through the unique working model of TrialNet. *Diabetologia*, **2017**, 60, 2139-2147	10.3	39
76	Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression. *Journal of Translational Medicine*, **2017**, 15, 40	8.5	30
75	Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection. *Frontiers in Immunology*, **2017**, 8, 811	8.4	10
74	Loss of immune tolerance to IL-2 in type 1 diabetes. *Nature Communications*, **2016**, 7, 13027	17.4	17
73	The Unusual Suspects in Allograft Rejection: Will T Regulatory Cell Therapy Arrest Them?. *Current Transplantation Reports*, **2016**, 3, 221-226	1.5	
72	Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. *Stem Cells*, **2016**, 34, 809-19	5.8	10
71	Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation. *Journal of Immunology*, **2015**, 194, 2117-27	5.3	17
70	Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes. *Diabetes*, **2015**, 64, 3873-84	0.9	16
69	Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice. *Diabetologia*, **2015**, 58, 1319-28	10.3	7
68	The streetlight effect in type 1 diabetes. *Diabetes*, **2015**, 64, 1081-90	0.9	46

67	Hurdles in therapy with regulatory T cells. *Science Translational Medicine*, **2015**, 7, 304ps18	17.5	114
66	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. *Current Diabetes Reports*, **2015**, 15, 115	5.6	9
65	Abnormalities of the Exocrine Pancreas in Type 1 Diabetes. *Current Diabetes Reports*, **2015**, 15, 79	5.6	63
64	CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. *Diabetes*, **2015**, 64, 1329-40	0.9	47
63	Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation. *Transplantation*, **2015**, 99, 1582-9	1.8	20
62	Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. *PLoS ONE*, **2015**, 10, e0142318	3.7	3
61	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. *Leukemia*, **2015**, 29, 396-405	10.7	98
60	PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner. *Clinical Immunology*, **2015**, 156, 98-108	9	7
59	Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice. *PLoS ONE*, **2015**, 10, e0127631	3.7	8
58	The protein tyrosine phosphatase PTPN22 controls forkhead box protein 3 T regulatory cell induction but is dispensable for T helper type 1 cell polarization. *Clinical and Experimental Immunology*, **2014**, 178, 178-89	6.2	18
57	Experiments by nature: lessons on type 1 diabetes. *Tissue Antigens*, **2014**, 83, 1-9		8
56	Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial. *Transplantation*, **2014**, 98, 1301-9	1.8	14
55	Neutrophils and type 1 autoimmune diabetes. *Current Opinion in Hematology*, **2014**, 21, 8-15	3.3	31
54	Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. *Current Topics in Microbiology and Immunology*, **2014**, 380, 39-68	3.3	161
53	Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. *Clinical Immunology*, **2013**, 149, 556-65	9	49
52	Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*, **2013**, 62, 2072-7	0.9	140
51	Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen. *American Journal of Transplantation*, **2013**, 13, 1963-75	8.7	35
50	Standardization in flow cytometry: correct sample handling as a priority. *Nature Reviews Immunology*, **2012**, 12, 864	36.5	8

49	Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. *Methods in Molecular Biology*, **2012**, 821, 279-93	1.4	48
48	Type 1 regulatory T (Tr1) cells: from the bench to the bedside. *Journal of Translational Medicine*, **2012**, 10,	8.5	1
47	Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. *Seminars in Immunology*, **2011**, 23, 182-94	10.7	40
46	Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. *PLoS ONE*, **2011**, 6, e28434	3.7	33
45	Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. *Blood*, **2011**, 118, 6772-82	2.2	110
44	Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. *Haematologica*, **2011**, 96, 1357-65	6.6	74
43	Th17 cells express interleukin-10 receptor and are controlled by Foxp3? and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. *Immunity*, **2011**, 34, 554-65	32.3	441
42	Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. *Diabetes*, **2011**, 60, 2903-13	0.9	162
41	Potential T regulatory cell therapy in transplantation: how far have we come and how far can we go?. *Transplant International*, **2010**, 23, 761-70	3	21
40	Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice. *PLoS ONE*, **2010**, 5, e10357	3.7	24
39	Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. *Diabetes*, **2010**, 59, 433-9	0.9	60
38	Modulation of early inflammatory reactions to promote engraftment and function of transplanted pancreatic islets in autoimmune diabetes. *Advances in Experimental Medicine and Biology*, **2010**, 654, 725-47	3.6	22
37	Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. *Blood*, **2010**, 116, 935-44	2.2	399
36	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. *Journal of Neuroimmunology*, **2010**, 220, 52-63	3.5	75
35	Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. *Diabetes*, **2009**, 58, 875-81	0.9	34
34	Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. *Diabetes*, **2009**, 58, 2277-84	0.9	61
33	The Tregs' world according to GARP. *European Journal of Immunology*, **2009**, 39, 3296-300	6.1	34
32	Comment on M. Guillot-Delost et al. (2008;10:834-846): Clinical-grade preparation of human natural regulatory T cells encoding the thymidine kinase suicide gene as a safety gene. *Journal of Gene Medicine*, **2009**, 11, 180-1	3.5	1

31	Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?. *Immunology Letters*, **2009**, 127, 1-7	4.1	11
30	The fate of human Treg cells. *Immunity*, **2009**, 30, 763-5	32.3	27
29	In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy. *Nature Reviews Immunology*, **2008**, 8, 1-1	36.5	1
28	STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. *International Immunology*, **2008**, 20, 421-31	4.9	142
27	Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. *Diabetes*, **2008**, 57, 2341-7	0.9	109
26	Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. *Novartis Foundation Symposium*, **2008**, 292, 174-83; discussion 183-6, 202-3		7
25	Human Type 1 T Regulatory Cells **2008**, 455-471		
24	Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. *Nature Reviews Immunology*, **2007**, 7, 585-98	36.5	418
23	WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. *Journal of Experimental Medicine*, **2007**, 204, 369-80	16.6	149
22	The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. *Blood*, **2007**, 110, 1788-96	2.2	29
21	Relevance of hyperglycemia on the timing of functional loss of allogeneic islet transplants: implication for mouse model. *Transplantation*, **2007**, 83, 167-73	1.8	25
20	A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. *Journal of Clinical Investigation*, **2007**, 117, 1260-9	15.9	87
19	Induction of transplantation tolerance via regulatory T cells. *Inflammation and Allergy: Drug Targets*, **2006**, 5, 157-65		15
18	Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. *Journal of Immunology*, **2006**, 177, 8338-47	5.3	566
17	Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. *Diabetes*, **2006**, 55, 1571-80	0.9	132
16	Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. *Experimental Cell Research*, **2006**, 312, 3872-9	4.2	28
15	Tr1 cells: from discovery to their clinical application. *Seminars in Immunology*, **2006**, 18, 120-7	10.7	225
14	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunological Reviews*, **2006**, 212, 28-50	11.3	966

13	Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. *Diabetes*, **2006**, 55, 40-9	0.9	67
12	Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. *Current Opinion in Hematology*, **2005**, 12, 451-6	3.3	17
11	Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. *Blood*, **2005**, 105, 4743-8	2.2	933
10	Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells. *Journal of Immunology*, **2005**, 174, 2680-6	5.3	91
9	IL-10-producing T regulatory type 1 cells and oral tolerance. *Annals of the New York Academy of Sciences*, **2004**, 1029, 142-53	6.5	80
8	The role of cytokines (and not only) in inducing and expanding T regulatory type 1 cells. *Transplantation*, **2004**, 77, S16-8	1.8	24
7	Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. *Blood*, **2004**, 103, 3700-9	2.2	183
6	The role of interleukin 10 in the control of autoimmunity. *Journal of Autoimmunity*, **2003**, 20, 269-72	15.5	38
5	The puzzling world of murine T regulatory cells. *Microbes and Infection*, **2002**, 4, 559-66	9.3	25
4	Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. *Journal of Experimental Medicine*, **2002**, 196, 1335-46	16.6	380
3	Beyond the usual suspects: a cholinergic route for panic attacks. *Molecular Psychiatry*, **2002**, 7, 239-46	15.1	24
2	Overlap of direct and indirect alloreactive T-cell repertoires when MHC polymorphism is limited to the peptide binding groove. *Human Immunology*, **2002**, 63, 91-100	2.3	5
1	Beyond the usual suspects: a cholinergic route for panic attacks		1